Kelun-Biotech's SKB118 PD-1 x VEGF bispecific antibody receives Chinese regulatory Investigational New Drug approval

Servier's Emi-Le receives US FDA breakthrough therapy designation for adenoid cystic carcinoma

Ranok Therapeutics reports positive Phase 1a clinical results for KRAS G12D inhibitor RNK08954

Hengrui Pharma and Bristol Myers Squibb agree to jointly advance oncology, haematology and immunology medicines

Anixa Biosciences reports extended survival signals in Phase 1 ovarian cancer CAR-T trial

Poolbeg Pharma secures Canadian patent grant for POLB 001

Harbour BioMed's HBM7004 receives US FDA IND clearance for Phase I trial

Innovent's IBI363 receives third Chinese regulatory BTD for MSS/pMMR CRC

Rznomics receives FDA RMAT designation for HCC candidate RZ‑001

Halozyme and GSK sign global drug‑delivery collaboration

Partner Therapeutics' BIZENGRI receives FDA Commissioner's National Priority Voucher for NRG1 fusion-positive cholangiocarcinoma

Diakonos Oncology's DOC1021 granted US FDA Fast Track Designation for unresectable or metastatic cutaneous melanoma

Racura Oncology identifies mechanism of action for (E,E)-bisantrene

ZYUS Life Sciences receives second US pain management patent

Citius Oncology to accelerate LYMPHIR commercialisation with up to USD36.5m in debt and equity capital